Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles
Overview
Authors
Affiliations
A reverse genetics approach which allows the generation of infectious defective rabies virus (RV) particles entirely from plasmid-encoded genomes and proteins (K.-K. Conzelmann and M. Schnell, J. Virol. 68:713-719, 1994) was used to investigate the ability of a heterologous lyssavirus glycoprotein (G) and chimeric G constructs to function in the formation of infectious RV-like particles. Virions containing a chloramphenicol acetyltransferase (CAT) reporter gene (SDI-CAT) were generated in cells simultaneously expressing the genomic RNA analog, the RV N, P, M, and L proteins, and engineered G constructs from transfected plasmids. The infectivity of particles was determined by a CAT assay after passage to helper virus-infected cells. The heterologous G protein from Eth-16 virus (Mokola virus, lyssavirus serotype 3) as well as a construct in which the ectodomain of RV G was fused to the cytoplasmic and transmembrane domains of the Eth-16 virus G rescued infectious SDI-CAT particles. In contrast, a chimeric protein composed of the amino-terminal half of the Eth-16 virus G and the carboxy-terminal half of RV G failed to produce infectious particles. Site-directed mutagenesis was used to convert the antigenic site III of RV G to the corresponding sequence of Eth-16 G. This chimeric protein rescued infectious SDI-CAT particles as efficiently as RV G. Virions containing the chimeric protein were specifically neutralized by an anti-Eth-16 virus serum and escaped neutralization by a monoclonal antibody directed against RV antigenic site III. The results show that entire structural domains as well as short surface epitopes of lyssavirus G proteins may be exchanged without affecting the structure required to mediate infection of cells.
Rabies virus as vector for development of vaccine: pros and cons.
Li Y, Zhou H, Li Q, Duan X, Liu F Front Vet Sci. 2024; 11:1475431.
PMID: 39386254 PMC: 11461460. DOI: 10.3389/fvets.2024.1475431.
Oberhuber M, Schopf A, Hennrich A, Santos-Mandujano R, Huhn A, Seitz S Viruses. 2021; 13(9).
PMID: 34578307 PMC: 8473393. DOI: 10.3390/v13091726.
Rhabdoviruses as vectors for vaccines and therapeutics.
Scher G, Schnell M Curr Opin Virol. 2020; 44:169-182.
PMID: 33130500 PMC: 8331071. DOI: 10.1016/j.coviro.2020.09.003.
Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.
Fisher C, Lowe D, Smith T, Yang Y, Hutson C, Wirblich C Cell Rep. 2020; 32(3):107920.
PMID: 32697993 PMC: 7373069. DOI: 10.1016/j.celrep.2020.107920.
Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.
Du Pont V, Wirblich C, Yoon J, Cox R, Schnell M, Plemper R J Virol. 2020; 94(13).
PMID: 32321812 PMC: 7307179. DOI: 10.1128/JVI.00321-20.